NanoViricides, Inc. Announces Leo Ehrlich as CFO
Tuesday July 26, 11:00 am ET
MIAMI--(BUSINESS WIRE)--July 26, 2005--NanoViricides, Inc. (Pink Sheets:NNVC - News), announced that Leo Ehrlich agreed to move from acting to permanent Chief Financial Officer of the Company. Mr. Ehrlich brings over 20 years of private and public company experience to the Company, including extensive experience in SEC reporting and guidelines.
Mr. Ehrlich became a certified public accountant in 1983 in NYC, and has been an investor in Theracour, the company from which NanoViricides licenses its core technology, since its inception. "My respect for Dr. Diwan has grown over the years we've been working together," noted Mr. Ehrlich. "His ability to talk science with industry leaders is unlike anything I've ever seen. He understands both the science and the business and I believe he will meet milestones set before him. I look forward to building this company with him."
About NanoViricides, Inc.
NanoViricides, Inc. is a development stage company that is creating special purpose nanomaterials for viral therapy. NanoViricides, Inc. has exclusive license in perpetuity for technologies developed by Theracour Pharma for the five virus types HIV, HCV, Herpes, Asian (bird) flu and Influenza. A NanoViricide(TM) is a flexible nanomaterial that is capable of encapsulating active pharmaceutical ingredients, and can be programmed to target a specific type of virus. When a NanoViricide(TM) polymeric micelle enters the patient's blood stream; it attacks and immobilizes circulating virus particles. Once this is done, the active pharmaceutical ingredient gets injected into the virus particle, destroying it completely. The company plans to develop novel NanoViricide(TM) drugs first against HIV, and anticipates that it will license the products to major pharmaceutical companies.
Contact:
NanoViricides, Inc., New York
Leo Ehrlich, 917-853-6440
Source: Nanoviricides, Inc.
biz.yahoo.com |
